Sector News

Novo Nordisk A/S: Changes in Novo Nordisk’s Executive Management

November 25, 2014
Life sciences
(GLOBE NEWSWIRE) – Following a change in the distribution of responsibilities among the members of its Executive Management, Novo Nordisk has reduced the number of executives from seven to six. In this connection Executive Vice President and Chief of Staffs Lise Kingo has decided to leave Novo Nordisk.
 
Her areas of responsibility will be taken over by other members of Executive Management. As from today:
 
– Corporate People & Organisation and Business Assurance report to Lars Fruergaard Jørgensen
– Corporate Stakeholder Engagement reports to Jakob Riis
– Corporate Communications reports to Lars Rebien Sørensen.
 
Commenting on the changes, Lars Rebien Sørensen, CEO, says: “I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company’s strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business. I wish her the best of luck in the future.”
 
Lise Kingo says: “I have really enjoyed being part of Novo Nordisk throughout my career, not least during my time as a member of its Executive Management. It has been a fantastic journey and I wish the company and my colleagues all the best in their onward journey. This is the beginning of a new chapter in which I plan to utilise my experience and insights in boards of companies and organisations internationally.”
 
Following the above-mentioned changes, Novo Nordisk’s Executive Management is now composed as follows:
 
Lars Rebien Sørensen, CEO (chief executive officer).
 
Kåre Schultz, president and COO (chief operating officer), responsible for Sales and Product Supply.
 
Jesper Brandgaard, executive vice president and CFO (chief financial officer), responsible for Finance, Legal, and Investor Relations.
 
Lars Fruergaard Jørgensen, executive vice president, responsible for Corporate IT, Corporate Quality, Corporate Development, Corporate People & Organisation and Business Assurance.
 
Jakob Riis, executive vice president, responsible for Marketing, Medical Affairs and Corporate Stakeholder Engagement. 
 
Mads Krogsgaard Thomsen, executive vice president and chief science officer, responsible for Research, Development and Regulatory Affairs.
 
Source: Novo Nordisk
 

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]